Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhideke granules is a Traditional Chinese Medicine (TCM) formulation developed by the Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine. It is primarily indicated for the treatment of acute tracheobronchitis, specifically targeting the wind-heat invading lung pattern, which is characterized by symptoms such as cough, viscous yellow sputum, fever, and sore throat. The drug is currently being evaluated in Phase 2 clinical trials (e.g., CTR20255066) to assess its efficacy and safety in relieving respiratory symptoms and promoting the resolution of inflammation in the bronchial tubes. As a TCM granule preparation, it consists of a proprietary blend of botanical extracts designed to clear heat, ventilate the lungs, and resolve phlegm.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhideke granules.